Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine
Article first published online: 15 NOV 2011
© 2011 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 271, Issue 2, pages 193–203, February 2012
How to Cite
Chao, C., Klein, N. P., Velicer, C. M., Sy, L. S., Slezak, J. M., Takhar, H., Ackerson, B., Cheetham, T. C., Hansen, J., Deosaransingh, K., Emery, M., Liaw, K.-L. and Jacobsen, S. J. (2012), Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. Journal of Internal Medicine, 271: 193–203. doi: 10.1111/j.1365-2796.2011.02467.x
- Issue published online: 17 JAN 2012
- Article first published online: 15 NOV 2011
- Accepted manuscript online: 4 OCT 2011 08:36AM EST
- autoimmune conditions;
- human papillomavirus;
- human papillomavirus vaccine;
- postlicensure safety study;
- vaccine safety
Abstract. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, Emery M, Liaw K-L, Jacobsen SJ (Kaiser Permanente Southern California, Pasadena, CA; Kaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California, Oakland, CA; Merck Research Laboratories, Upper Gwynedd, PA; South Bay Medical Center, Kaiser Permanente Southern California, Los Angeles, CA; and Kaiser Permanente Southern California, Downey, CA, USA). Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012; 271: 193–203.
Objective. An observational safety study of the quadrivalent human papillomavirus vaccine (HPV4) in women was conducted. This report presents findings from autoimmune surveillance.
Design. Subjects were followed for 180 days after each HPV4 dose for new diagnoses of 16 prespecified autoimmune conditions.
Setting. Two managed care organizations in California.
Subjects. Number of 189 629 women who received ≥1 dose of HPV4 between 08/2006 and 03/2008.
Outcome. Potential new-onset autoimmune condition cases amongst HPV4 recipients were identified by electronic medical records. Medical records of those with ≥12-month health plan membership prior to vaccination were reviewed by clinicians to confirm the diagnosis and determine the date of disease onset. The incidence of each autoimmune condition was estimated for unvaccinated women at one study site using multiple imputations and compared with that observed in vaccinated women. Incidence rate ratios (IRR) were calculated. Findings were reviewed by an independent Safety Review Committee (SRC).
Results. Overall, 1014 potential new-onset cases were electronically identified; 719 were eligible for case review; 31–40% were confirmed as new onset. Of these, no cluster of disease onset in relation to vaccination timing, dose sequence or age was found for any autoimmune condition. None of the estimated IRR was significantly elevated except Hashimoto’s disease [IRR = 1.29, 95% confidence interval: 1.08–1.56]. Further investigation of temporal relationship and biological plausibility revealed no consistent evidence for a safety signal for autoimmune thyroid conditions. The SRC and the investigators identified no autoimmune safety concerns in this study.
Conclusions. No autoimmune safety signal was found in women vaccinated with HPV4.